Codexis Inc(CDXS) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Codexis, Inc. discovers, develops, and sells protein catalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

Current Price

$19.34

RSI

9.681

Beta:

1.290678

March 01, 2021
25M
-3M

21.294 %
-19.068 %
-520.952 %
-367.160 %

$69,056,000
$68,458,000
$60,594,000
$50,024,000
$48,837,000
$41,804,000
0.874 %
12.978 %
21.130 %
2.431 %
16.824 %

$-23,671,000
$-11,918,000
$-10,915,000
$-22,915,000
$-8,598,000
$-7,919,000
-49.651 %
-8.416 %
109.940 %
-62.479 %
-7.897 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.